Brinter's scienfic developer, Antti Arjonen, (PhD, Cell/Cellular and Molecular Biology) contributes to ovarian cancer research. The scientific article was published by Clinical Oncology and Research journal. [...]
“Bioprinting’s importance for pharmaceutical analysis is paramount now, not only for potential Covid-19 treatments but also for testing treatments for cancer and other diseases,” states a recent article from [...]
Brinter is assisting the University of Gothenburg in the RESTORE project with the optimization of the nanocellulose/alginate-based bioink to improve its printability and cartilage tissue regeneration. For test purposes, [...]
Horizon 2020 Novum project news: In a major step forward in the field of additive manufacturing, BRINTER has demonstrated that it can successfully print constructs from cellulose granulates, a [...]
Brinter customers and partners frequently ask us about the history of the modular 3D bioprinter - Brinter. Here you can see the important milestones in a one-pager. [...]
In May 2020, Brinter Ltd. was selected as one of the top eight 3D bioprinting startups in the world by StartUs Insights. The Austrian data science and research company [...]
Brinter® 3D bioprinting application specialists actively contribute to cancer research, keeping up with the future demands of 3D bioprinting. Please take a look at the recent research paper published [...]
Brinter® has successfully tested 3D printing of UV-curable silicone rubber, Silopren™ UV LSR 2030 by Momentive Performance Materials. Check out our video clip about the printing process. [...]
Brinter was selected as one of the few startups into the Finnish national level ProHealth program for early-phase growth companies. The ProHealth Accelerator program is a coaching, networking, and [...]
Granulate-based multi-material 3D printing was successfully carried out with Brinter® platform using two different cellulose-based materials. The first material with high cellulose content is developed by VTT as part [...]
